Skip to main content

Closed

CUE: Cue Biopharma, Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Revenue growth+195.7% / yr

Operating margin-59.8%

ROIC-78.2%

Financially safe

Stretched

Debt / equity0.16×

Interest coverage-111.9×

Current ratio3.57×

Cue Biopharma, Inc.

CUENASDAQ Capital Market·USD·Closed

Cue Biopharma, Inc.

CUENASDAQ·USD·Closed

$26.84

−11.71%

$26.84

−$3.56 (11.71%)

52W Range

54thpctl

Volume

0.94×avg

Mkt Cap

70.53MUSD

P/E

-4.9TTM

Div Yield

–ann

52W Range

54thpctl

Volume

0.94×avg

Market Cap

70.53MUSD

P/E Ratio

-4.9TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings